TRIB
Trinity Biotech PLC
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Trinity Biotech PLC
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No changes.
No changes.
Largest filed tie
0
filed ties
—
No peers for Trinity Biotech PLC yet.
No peers for Trinity Biotech PLC yet.
Annual filing, covered
20-F parsed · Apr 30 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Apr 30 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
—
Expected move
No implied move.
| Manager | Value | % base | |
|---|---|---|---|
| Hunter | $257,000 | 63.48% | +23.31% |
| Williams & Novak | $54,643 | 13.50% | +30.56% |
| Susquehanna International | $29,826 | 7.37% | +435.38% |
| Moss Adams Wealth | $9,979 | 2.46% | 0.00% |
| Cambridge Investment Research | $9,000 | 2.22% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Hunter | $257,000 | 63.48% | +23.31% |
| Williams & Novak | $54,643 | 13.50% | +30.56% |
| Susquehanna International | $29,826 | 7.37% | +435.38% |
| Moss Adams Wealth | $9,979 | 2.46% | 0.00% |
| Cambridge Investment Research | $9,000 | 2.22% | 0.00% |
+27.31%
shares held · 10 largest managers
Trinity Biotech PLC
6.15
−0.48 · −7.24%
post 6.15 0.00%